55 results about "Chronic sinusitis" patented technology

Methods of treating a central airway obstruction (CAO), benign airway stenosis, asthma, chronic obstructive pulmonary disease (COPD), or an airway tumor in a human subject, methods of treating chronic rhinosinusitis (CRS) or chronic rhinosinusitis with nasal polyps (CRSwNP) in a human subject, methods of treating a eustachian tube disorder in a human subject, and devices and systems for performing the methods. A method of treating a central airway obstruction (CAO), benign airway stenosis, asthma, chronic obstructive pulmonary disease (COPD), or an airway tumor in a human subject includes inserting a drug-coated balloon catheter into a target site in a trachea, mainstem bronchus, bronchus intermedius, lobar bronchus, segmental bronchus, or sub-segmental bronchus, wherein the balloon is coated with a coating layer including the therapeutic agent and one or more additives. The therapeutic agent includes paclitaxel, sirolimus, or a derivative thereof. The method includes inflating the balloon to dilate the airway and deliver a therapeutic agent to the airway wall. The method includes deflating the balloon. The method also includes withdrawing the balloon catheter from the target site.

Methods for treating or preventing chronic rhinosinusitis without nasal polyps (CRSsNP) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The invention discloses a chronic sinusitis CT (Computed Tomography) image automatic typing and severity assessment method and a chronic sinusitis CT image automatic typing and severity assessment system based on deep learning. The method comprises the following steps: acquiring paranasal sinus CT image data of a chronic sinusitis patient and an associated clinical tag; carrying out standardization processing on the CT image, wherein the standardization processing comprises gray level normalization, denoising and region-of-interest segmentation; a multi-task deep learning model is constructed, an improved 3D Re < s> Ne < t-50 > architecture is adopted by a typing sub-model to output an immune endotype classification result, and a severity evaluation sub-model segments a lesion area based on a U-Ne < t + + > structure and automatically calculates a severity level; integrating model output to generate individualized treatment suggestions; and superposing a labeling result through the thermodynamic diagram and embedding the labeling result into a hospital PACS system. Accurate typing and evaluation of chronic nasosinusitis are achieved, and diagnosis efficiency and clinical decision support capability are improved.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

The invention relates to biodegradable intranasal system for the sustained-release of fluticasone propionate in the intranasal cavity, said system comprising a biodegradable polyester matrix that comprises the fluticasone propionate as the active ingredient to be released in the intranasal cavity, wherein the polyester is selected from the list of poly(L,D-lactic acid) (PLA), poly(caprolactone) (PCL), their copolymers such as PLA-PCL, and mixtures thereof; and a method for preparing said system. The invention also relates to a kit comprising the system of the invention and the means of insertion of the system into the nasal cavity. The invention further relates to fluticasone propionate for use for treating chronic rhinitis or chronic sinusitis, wherein the fluticasone propionate is in a form suitable for administration in the nasal cavity by means of the biodegradable intranasal system of the invention.

The present application belongs to the field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating chronic rhinosinusitis in children, a compound preparation of the traditional Chinese medicine composition and application. The present application firstly provides an optimized traditional Chinese medicine formula, which takes Radix Saposhnikoviae, Magnolia flower and Xanthium fruit as monarch drugs, and the weight ratio of the monarch drugs is in the range of 1:6:1 to 1:2:1, which has a significant reducing effect on the expression level of inflammatory factors in chronic rhinosinusitis mice in vivo. Further, the present application provides a compound preparation of the traditional Chinese medicine formula for treating chronic rhinosinusitis in children combined with probiotics, and surprisingly finds that the compound preparation 2 has a more efficient and significant treatment effect than other compound preparations and the control group. The traditional Chinese medicine formula and the probiotics have a synergistic effect when combined in a weight ratio of 10:2. The present application has important significance in providing a preparation with the characteristics of no drug resistance, no side effect and fast effect for children with chronic rhinosinusitis.

The invention belongs to the technical field of biological medicines, and relates to an efficient affinity anti-human IL-33 monoclonal antibody and a preparation method thereof. The monoclonal antibody provided by the invention has good specificity and affinity, accurately targets a key cell factor IL-33, and effectively blocks a binding path between the key cell factor IL-33 and a receptor ST2. As a core factor mediating various inflammatory diseases, such as asthma, allergic dermatitis, chronic sinusitis, chronic obstructive pulmonary disease (COPD) and the like, IL-33 is crucial in intervention of a regulation mechanism for disease treatment. The monoclonal antibody disclosed by the invention is novel in sequence, and provides a new thought for preparation of the medicine by inhibiting IL-33 mediated inflammatory reaction.

The invention belongs to the technical field of medicine, and discloses a medicinal sponge sheet for inhibiting growth of nasal polyp, the medicinal sponge sheet is composed of a medical grade absorptive gelatin sponge base material, triamcinolone acetonide and hydroxypropyl methyl cellulose, the medicinal sponge sheet adopts the medical gelatin base material with the porosity of 95% and the water absorption expansion rate of less than or equal to 30%, the size is 60mm * 20mm * 5mm, each sheet loads 60mg of triamcinolone acetonide, and the hydroxypropyl methyl cellulose is added into the medicinal sponge sheet. And 10% of hydroxypropyl methyl cellulose with the molecular weight of 35000 Da and the viscosity of 700 mPa.s is supplemented to construct a slow release system. Efficient and safe treatment of chronic nasosinusitis with nasal polyp is achieved through multi-dimensional innovative design, the three-dimensional interpenetrating pore structure of the medical gelatin base material provides an ideal carrier for drug release, 60%-70% of triamcinolone acetonide is continuously released within 7 days through the gradient slow release technology, a local high-concentration microenvironment is constructed, and the effect of treating chronic nasosinusitis with nasal polyp is achieved. The device directly acts on the polyp root to block an inflammation cascade reaction; in the formula, hydroxypropyl methyl cellulose is used as a core slow-release carrier.

Methods for treating or preventing chronic rhinosinusitis without nasal polyps (CRSsNP) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The present disclosure relates generally to methods of treating chronic sinusitis with or without nasal polyp using antibodies specific for thymic stromal lymphopoietin (TSLP).

The invention discloses a chronic sinusitis full-automatic segmentation method based on deep learning and related equipment. The method comprises the following steps: acquiring paranasal sinus CT image data of a chronic sinusitis patient, wherein the paranasal sinus CT image data comprises paranasal sinus CT image data of patients with different genders, ages and disease course stages; dividing the paranasal sinus CT image data into a training verification set and a test set, and training an nnUNetV2 model based on the training verification set to obtain a chronic sinusitis region-of-interest segmentation model; and performing full-automatic segmentation of chronic sinusitis on CT image data of a target patient through the segmentation model of the region-of-interest of chronic sinusitis. The problems of low segmentation efficiency, high subjectivity and difficulty in precise segmentation of the chronic sinusitis region-of-interest caused by high complexity and individual variability of the anatomical structure of the nasal cavity and the paranasal sinus can be solved.

Devices for therapeutic nasal neuromodulation and associated systems and methods are disclosed herein. A system for therapeutic neuromodulation in a nasal region configured in accordance with embodiments of the present technology can include, for example, a shaft and a therapeutic element at a distal portion of the shaft. The shaft can locate the distal portion intraluminally at a target site inferior to a patient's sphenopalatine foramen. The therapeutic element can include an energy delivery element configured to therapeutically modulate postganglionic parasympathetic nerves at microforamina of a palatine bone of the human patient for the treatment of rhinitis or other indications. In other embodiments, the therapeutic element can be configured to therapeutically modulate nerves that innervate the frontal, ethmoidal, sphenoidal, and maxillary sinuses for the treatment of chronic sinusitis.

Disclosed herein are antigen binding proteins, e.g. an antibody, which bind to IL-5, for use in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), wherein the nasal polyps score and / or mean nasal obstruction score is improved.

The invention discloses a medical drug-loading paranasal sinus stent as well as a preparation method and application thereof. The medical drug-loaded paranasal sinus stent comprises a nasosinusitis treatment drug and medical catalyst-free polycaprolactone loaded with the nasosinusitis treatment drug, the drug loading capacity of the medical drug-loading paranasal sinus stent is 2 to 20 weight percent; the 24-hour burst release rate of the medical drug-loading paranasal sinus stent is lt; the continuous release time is more than or equal to 4 weeks; wherein the medical catalyst-free polycaprolactone is prepared by carrying out ring opening polymerization on double ether bond oxalic acid amide dihydric alcohol serving as an initiator and caprolactone. According to the medical drug-loaded paranasal sinus stent, the risk of catalyst residue is completely eradicated from the source, the stent implantation safety is guaranteed, the controllable degradation performance and the drug slow release effect of the stent can meet the paranasal sinus postoperative repair requirement, and the medical drug-loaded paranasal sinus stent is suitable for in-vivo implantation and supporting of people or animals and has important prospects in the field of chronic nasosinusitis postoperative treatment.

Devices for therapeutic nasal neuromodulation and associated systems and methods are disclosed herein. A system for therapeutic neuromodulation in a nasal region configured in accordance with embodiments of the present technology can include, for example, a shaft and a therapeutic element at a distal portion of the shaft. The shaft can locate the distal portion intraluminally at a target site inferior to a patient's sphenopalatine foramen. The therapeutic element can include an energy delivery element configured to therapeutically modulate postganglionic parasympathetic nerves at microforamina of a palatine bone of the human patient for the treatment of rhinitis or other indications. In other embodiments, the therapeutic element can be configured to therapeutically modulate nerves that innervate the frontal, ethmoidal, sphenoidal, and maxillary sinuses for the treatment of chronic sinusitis.

A method of treating a patient with of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, the method comprising administering 150 mg / mL omalizumab formulation, wherein the omalizumab is administered subcutaneously by a syringe.

The invention discloses a chronic nasosinusitis auxiliary typing method based on radiomics data and related equipment. The method comprises the following steps: acquiring paranasal sinus radiomics data, clinical feature data and biological sample analysis result data of a chronic sinusitis patient; dividing the paranasal sinus radiomics data into a plurality of image clustering categories by adopting an unsupervised clustering algorithm, and associating clinical feature data and biological sample analysis result data corresponding to different image clustering categories respectively; and analyzing clinical feature data differences and biological sample analysis result data differences among different image clustering categories, and constructing a systematic mapping relationship between the image clustering categories and clinical pathological typing so as to carry out chronic sinusitis auxiliary typing. The problems that in typing research of chronic nasosinusitis, traditional intrinsic typing needs to depend on complex and expensive biological sample examination, generalizability is not high, and sampling cannot completely reflect individual heterogeneity of patients and is invasive can be solved.

The invention belongs to the technical field of biological medicines, and relates to a monoclonal antibody capable of being specifically combined with IL-33 as well as a preparation method and application thereof. The monoclonal antibody capable of being specifically bound with the IL-33 can be specifically bound with the IL-33 in a high-affinity mode, and therefore binding of the IL-33 and a receptor ST2 of the IL-33 is effectively blocked. IL-33 is an important cell factor, and plays a key role in the occurrence and development of various diseases, such as asthma, specific reactive / allergic dermatitis, chronic sinusitis, chronic obstructive pulmonary disease (COPD) and the like. By blocking the combination of IL-33 and ST2, the antibody can inhibit inflammatory reactions mediated by IL-33, and a new strategy is provided for the treatment of these diseases.

Provided are combination dosing regimens comprising administering a monoclonal antibody, such as dupilumab, and hyaluronidase. Combinations and compositions containing the monoclonal antibody and hyaluronidase are provided. The dosing regimens and combinations with dupilumab are for treating or preventing allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis, eosinophilic esophagitis, and prurigo nodularis.

The invention discloses a medicinal moxa composition for preventing and treating chronic nasosinusitis and kidney stone co-disease. The medicinal moxa composition comprises asarum, gardenia jasminoides, agilawood and moxa. The medicinal moxa composition disclosed by the invention generates an external preparation with synergistic effects of smoke, medicinal gas and heating power through combustion. Volatile components of the four medicines are burnt to form a composite pharmacodynamic system which is absorbed by skin, mucous membrane and respiratory system to generate a unique treatment effect. The medicinal moxa composition can realize cold-warm balance, multi-target coordination, immunoregulation, anti-inflammatory action and diuresis metabolism regulation through the synergistic effect of heating power and volatile matters, so that the dual effects of preventing and treating nasosinusitis and kidney stone are achieved. Due to the external use characteristic, the traditional Chinese medicine composition can directly act on body surface acupuncture points and is conducted to related viscera through meridians and collaterals to form a treatment path from the outside to the inside.

This invention belongs to the field of nanomedicine delivery and immunotherapy technology, and provides a treatment for CD4-positive conditions including asthma, inflammatory bowel disease, and chronic sinusitis. + A CD4-targeting Runx3-siRNA nanodelivery system for T-cell-mediated chronic inflammatory diseases comprises lipid nanoparticles loaded with Runx3-siRNA and a CD4-targeting ligand coupled to the surface of the lipid nanoparticles. This system enables targeting of pathogenic CD4-mediated chronic inflammatory diseases. + T-cell-specific delivery and Runx3 gene silencing; lipid nanoparticles composed of ionic lipids, helper lipids, cholesterol, and PEG-modified lipids, with anti-CD4 antibodies anchored to the surface via maleimide-thiol coupling; this invention targets pathogenic CD4... + Specific delivery of T cells and silencing of the Runx3 gene solve the problems of side effects caused by non-specific immunosuppression and insufficient targeting of lipid nanoparticles.

Devices for therapeutic nasal neuromodulation and associated systems and methods are disclosed herein. A system for therapeutic neuromodulation in a nasal region configured in accordance with embodiments of the present technology can include, for example, a shaft and a therapeutic element at a distal portion of the shaft. The shaft can locate the distal portion intraluminally at a target site inferior to a patient's sphenopalatine foramen. The therapeutic element can include an energy delivery element configured to therapeutically modulate postganglionic parasympathetic nerves at microforamina of a palatine bone of the human patient for the treatment of rhinitis or other indications. In other embodiments, the therapeutic element can be configured to therapeutically modulate nerves that innervate the frontal, ethmoidal, sphenoidal, and maxillary sinuses for the treatment of chronic sinusitis.

This disclosure describes, inter alia, materials, devices, kits and methods that may be used to treat chronic sinusitis. An implant is configured to fit inside of the middle meatus of a human nasal cavity. The implant includes a therapeutic-agent formulation containing a layer of over 2000 micrograms of mometasone furoate. The implant releases the mometasone furoate for more than 12 weeks. A second implant can also be provided configured to fit inside the middle meatus. The second implant also includes a therapeutic-agent formulation containing a layer of over 2000 micrograms of mometasone furoate, and releases the mometasone furoate for more than 12 weeks.

The invention provides a nasal polyp automatic grading model training method, a scoring method, a system and equipment, and relates to the technical field of image analysis. In order to solve the problem that automatic grading of nasal polyp of a chronic sinusitis patient is difficult to realize in the prior art, an endoscopic image set containing different grades of nasal polyp score marking information is constructed based on nasal endoscopic image data of the patient, and a preset target detection model is trained by using the image set, so that the classification of the nasal polyp of the chronic sinusitis patient is realized. Therefore, the preset target detection model can directly learn and internalize the international standard of nasal polyp grade scoring, and then the preset target detection model can stably learn the nasal endoscope characteristics covering each scoring grade through the full-process training of data enhancement, cross validation and hyper-parameter tuning, so that the accuracy of the nasal endoscopy is improved. And the output nasal polyp grade score has both automation and accuracy, so that the core technical bottleneck of automatic nasal polyp grading under the endoscope is solved.

The application belongs to the technical field of biology, and discloses an anti-CSF3R antibody and application thereof, wherein the anti-CSF3R antibody comprises a heavy chain variable region VH and a light chain variable region VL, the heavy chain variable region VH comprises VHCDR1, VHCDR2 and VHCDR3, and the light chain variable region VL comprises VLCDR1, VLCDR2 and VLCDR3. The anti-CSF3R antibody can block the interaction between CSF3R and a ligand G-CSF, and then inhibit G-CSF signal transmission, neutrophil survival and migration, and the effect is equivalent to that of a reference antibody CSL324, and the anti-CSF3R antibody can be used for treating chronic sinusitis.

The invention discloses an application of a CGRP receptor small molecule antagonist in preparation of a medicine for treating eosinophilic chronic sinusitis with nasal polyp. The pharmaceutical preparation is composed of an effective amount of a CGRP receptor small molecule antagonist and pharmaceutically acceptable auxiliary materials, the dosage form is nasal spray / nose drop / irrigation, and the pharmaceutical preparation is simple and convenient in administration route, easy to operate and convenient for patients to use. According to the invention, by inhibiting CGRP-mediated mast cell activation, eosinophilic granulocyte inflammation is significantly relieved, and especially, the traditional Chinese medicine composition has a definite treatment advantage on eosinophilic granulocyte nasal polyp; and compared with a biological agent of a targeted type 2 cytokine, the small molecule compound is safer, simpler and more convenient to obtain, the treatment cost of a patient can be remarkably reduced, and a new efficient and economic choice is provided for nasal polyp treatment.

The invention generally relates to systems and methods for targeting of specific tissue(s) of interest within a sino-nasal region of a patient, specifically sinus regions (i.e., ostia and sinus cavities), for the treatment of chronic sinusitis conditions.

To provide methods for getting data to classify patients with chronic sinusitis, to provide kits for classifying patients with chronic sinusitis, to provide arrays for classifying patients with chronic sinusitis, and to provide apparatus for classifying patients with chronic sinusitis.SOLUTION: One embodiment of the present invention uses the expression of at least three genes contained in a gene cluster consisting of a plurality of specific genes as an index.SELECTED DRAWING: None

The present invention relates to materials, devices, kits and methods for use in treatment of patients having a sinus condition such as severe chronic rhinosinusitis. The implant configured to fit ins

A method of delivering a substance, such as one or more of a triptan, a nasal steroid or carbon dioxide gas, to the nasal cavity of a subject, in particular for the treatment of headaches, for example, migraine, or rhinosinusitis, for example, chronic rhinosinusitis, optionally with polyps, the method comprising the steps of fitting a nosepiece to one nostril of the subject, delivering the substance through the nosepiece to the posterior region of the nasal cavity of the subject.